Sun Pharma wins US antitrust appeal over Lipitor deal

Sun Pharmaceutical Industries has secured a favourable verdict in the United States antitrust litigation related to a 2008 patent settlement agreement with Pfizer over generic Lipitor (Atorvastatin). The United States Court of Appeals for the Third Circuit affirmed the District Court's order granting summary judgment entirely in favour of the company and its subsidiaries. The appellate court also upheld the District Court's orders denying class certification to the plaintiffs.

The antitrust plaintiffs had alleged that the settlement agreement unlawfully delayed generic competition for Lipitor. Sun Pharma stated that the decision brings the litigation substantially to a close, subject to any further remedies available to the plaintiffs under applicable law. The judgment was announced on Monday, August 17, 2026.